Gilbert M. Rishton

Cardax Pharmaceuticals, Inc. develops proprietary small molecule therapies for large unmet medical needs. It develops proprietary small molecule therapies for large unmet needs where oxidative stress and inflammation play important causative roles-including cardiovascular disease, hepatitis, macular degeneration and many cancers. The company's proprietary, synthetic, natural compound derivatives represent a novel treatment approach that offers efficacy along with an outstanding safety profile, oral bioavailability and tissue selectivity. Cardax Pharmaceuticals was founded by David G. Watumull and Samuelf Lockwood in May 2006 and is headquartered in Honolulu, HI.